Guidelines here https://www.xprize.org/prizes/healthspan/guidelines
Criteria for this market: improvements in function relative to age-related declines expected, by at least 10-years
Competing teams will develop and test therapeutics that restore muscle, cognition, and immune function by a minimum of 10 years with a goal of 20 years and extend healthy life.
Awarding is indexed to improvements in function relative to age-related declines expected over 10-years ($61M), 15-years ($71M), or 20-years ($81M).
$20M in milestone awards, with $10M allocated to each milestone .
Plus an additional $10M to the 1st Place in XPRIZE FSHD Bonus track to restore muscle function.
1,000Status: XPRIZE named 20 finalists on 11 August 2026, ten of them with $1M Milestone 2 awards (AgelessRx, Goda Lab, Johns Hopkins-Suninflam, Longeveron, Minicircle, Mitochondrial All Stars, NYC-Vita, RETRO-EPIGERNA, RPRGAON-Progeria, TIME TRAVELER-Plant). The finals test restoration of muscle, cognition and immune function by at least 10 years within one year of treatment in adults aged 50 to 90, with the grand prize decided in 2030, so note this market closes in December 2027, before the final result exists. For scale on the 10-year bar: the largest replicated lifespan effect of any drug in a mammal is about a quarter (rapamycin in the NIA mouse program), and the one species where lifespan itself is now being tested in placebo-controlled trials is the dog, with readouts around 2029 to 2031. Which species gets the first approved lifespan drug (mine): /w0lph/which-species-will-get-the-first-re